secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001125345-22-000089
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q2 net loss $41.3M; cuts 15% workforce, extends cash runway to 2024
-------------------------------------------------------------------------------

- Net loss $41.3M vs $39.9M YoY; cash $133.7M at June 30, plus $34.5M in July payments from partners.
- Workforce reduction of ~15% and closure of Brisbane and Rockville sites to reduce costs.
- Received $30M milestone from Incyte; $60M milestone due upon teplizumab approval (PDUFA Nov 17, 2022).
- Plan to start MGC018 Phase 2/3 TAMARACK study in mCRPC by year-end; interim data from Phase 2 by end 2024.
- Lorigerlimab Phase 1/2 enrollment complete; data update expected early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000089/0001125345-22-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000089/mgnx-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001125345-22-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer